| 產(chǎn)品編號(hào) | bs-1905R |
| 英文名稱(chēng) | Synphilin-1 Rabbit pAb |
| 中文名稱(chēng) | 核突觸蛋白相互作用蛋白1抗體 |
| 別 名 | Synphilin-1; Synphilin1; Synphilin 1; alpha-synuclein-interacting protein; Sncaip; Syph1, Syph 1, Syph-1; alpha synuclein interacting protein; MGC39814; SNCAIP; SNCAP_HUMAN; Sph1; Synuclein alpha interacting protein(synphilin); SYPH 1. |
 |
Specific References (1) | bs-1905R has been referenced in 1 publications.
[IF=5.808] Guo Q et al. Small interfering RNA delivery to the neurons near the amyloid plaques for improved treatment of Alzheimer's disease. Acta Pharm Sin B. 2019 May;9(3):590-603. WB ; Mouse.
|
| 研究領(lǐng)域 | 細(xì)胞生物 免疫學(xué) 神經(jīng)生物學(xué) |
| 抗體來(lái)源 | Rabbit |
| 克隆類(lèi)型 | Polyclonal |
| 克 隆 號(hào) | |
| 交叉反應(yīng) | Rat (predicted: Human,Mouse,Rabbit,Pig,Sheep,Cow,Chicken,Dog,GuineaPig,Horse) |
| 產(chǎn)品應(yīng)用 | IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500,ELISA=1:5000-10000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 100 kDa |
| 檢測(cè)分子量 | |
| 細(xì)胞定位 | 細(xì)胞漿 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human Synphilin-1: 51-150/919 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
This gene encodes a protein containing several protein-protein interaction domains, including ankyrin-like repeats, a coiled-coil domain, and an ATP/GTP-binding motif. The encoded protein interacts with alpha-synuclein in neuronal tissue and may play a role in the formation of cytoplasmic inclusions and neurodegeneration. A mutation in this gene has been associated with Parkinson's disease. Alternatively spliced transcript variants encoding different isoforms of this gene have been described, but the full-length nature of only two have been determined. [provided by RefSeq, Jul 2011]. Function: Isoform 2 inhibits the ubiquitin ligase activity of SIAH1 and inhibits proteasomal degradation of target proteins. Isoform 2 inhibits autoubiquitination and proteasomal degradation of SIAH1, and thereby increases cellular levels of SIAH. Isoform 2 modulates SNCA monoubiquitination by SIAH1. Subunit: Homodimer (Probable). Heterodimer of isoform 1 and isoform 2 (Probable). Interacts with SIAH1, SIAH2, SNCA, RNF19A AND PARK2. Isoform 2 has a strong tendency to form aggregates and can sequester isoform 1. Subcellular Location: Cytoplasm. Detected in cytoplasmic inclusion bodies, together with SNCA. Tissue Specificity: Detected in brain (at protein level). Widely expressed, with highest levels in brain, heart and placenta. Post-translational modifications: Ubiquitinated; mediated by SIAH1, SIAH2 or RNF19A and leading to its subsequent proteasomal degradation. In the absence of proteasomal degradation, ubiquitinated SNCAIP accumulates in cytoplasmic inclusion bodies. Isoform 2 is subject to limited ubiquitination that does not lead to proteasomal degradation. DISEASE: Parkinson disease (PARK) [MIM:168600]: A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features. Note=Disease susceptibility may be associated with variations affecting the gene represented in this entry. Similarity: Contains 6 ANK repeats. SWISS: Q9Y6H5 Gene ID: 9627 Database links: Entrez Gene: 9627 Human Entrez Gene: 67847 Mouse Omim: 603779 Human SwissProt: Q9Y6H5 Human SwissProt: Q99ME3 Mouse Unigene: 426463 Human Unigene: 292168 Mouse |
